Charles Cherington

Charles Cherington is a declared insider at 2 companies (board member); the most frequent names are Comera Life Sciences Holdings, Inc. and Ernexa Therapeutics Inc. We count 16 filings; the first trade dates from 1 June 2021 and the latest from 10 February 2026.

In open-market terms, that means 14 purchases worth €4.8M on one side and 1 sale worth €2.6M on the other. The amount is not disclosed for 10 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2026, the count stands at 1 purchase and no sales.

A typical purchase (the median) is worth €1.2M. On 1 out of 6 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 17 February 2026, the filings show an open-market purchase worth €1.7M in Ernexa Therapeutics Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.